143 related articles for article (PubMed ID: 27063172)
41. The Role of Total Oxidant and Antioxidant Levels in Follicular Fluid in Unexplained İnfertility.
Topdagi SK; Topdagi YE; Ozdemir I; Borekci B
Niger J Clin Pract; 2024 Jun; 27(6):739-747. PubMed ID: 38943298
[TBL] [Abstract][Full Text] [Related]
42. Advanced oxidation protein products and serum total oxidant/antioxidant status levels in rosacea.
Erdogan HK; Bulur I; Kocaturk E; Saracoglu ZN; Alatas O; Bilgin M
Postepy Dermatol Alergol; 2018 Jun; 35(3):304-308. PubMed ID: 30008650
[TBL] [Abstract][Full Text] [Related]
43. [Effect of polycystic ovary syndrome treated with the periodic therapy of acupuncture].
Yang D; Zhao M; Tan J
Zhongguo Zhen Jiu; 2017 Aug; 37(8):825-829. PubMed ID: 29231341
[TBL] [Abstract][Full Text] [Related]
44. Thiol level and total oxidant/antioxidant status in patients with COVID-19 infection.
Çakırca G; Damar Çakırca T; Üstünel M; Torun A; Koyuncu İ
Ir J Med Sci; 2022 Aug; 191(4):1925-1930. PubMed ID: 34467472
[TBL] [Abstract][Full Text] [Related]
45. Analysis of the diagnostic efficiency of serum oxidative stress parameters in patients with breast cancer at various clinical stages.
Feng JF; Lu L; Dai CM; Wang D; Yang YH; Yang YW; Liu YS
Clin Biochem; 2016 Jun; 49(9):692-698. PubMed ID: 26899366
[TBL] [Abstract][Full Text] [Related]
46. Serum and whole blood Zn, Cu and Mn profiles and their relation to redox status in lung cancer patients.
Zabłocka-Słowińska K; Płaczkowska S; Prescha A; Pawełczyk K; Porębska I; Kosacka M; Pawlik-Sobecka L; Grajeta H
J Trace Elem Med Biol; 2018 Jan; 45():78-84. PubMed ID: 29173487
[TBL] [Abstract][Full Text] [Related]
47. Increased thrombin-activatable fibrinolysis inhibitor antigen levels as a clue for prothrombotic state in polycystic ovary syndrome.
Karakurt F; Gumus II; Bavbek N; Kargili A; Koca C; Selcoki Y; Ozbek M; Kosar A; Akcay A
Gynecol Endocrinol; 2008 Sep; 24(9):491-7. PubMed ID: 18958767
[TBL] [Abstract][Full Text] [Related]
48. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study.
Morin-Papunen L; Vauhkonen I; Koivunen R; Ruokonen A; Martikainen H; Tapanainen JS
J Clin Endocrinol Metab; 2003 Jan; 88(1):148-56. PubMed ID: 12519844
[TBL] [Abstract][Full Text] [Related]
49. Increased prolidase activity and oxidative stress in PCOS.
Hilali N; Vural M; Camuzcuoglu H; Camuzcuoglu A; Aksoy N
Clin Endocrinol (Oxf); 2013 Jul; 79(1):105-10. PubMed ID: 23163753
[TBL] [Abstract][Full Text] [Related]
50. [Treatment of polycystic ovary syndrome and related infertility with clomiphene resistance by compound cyproterone acetate].
Tao Y; Dai Q; Zhang D
Zhonghua Fu Chan Ke Za Zhi; 1999 Sep; 34(9):528-32. PubMed ID: 11360636
[TBL] [Abstract][Full Text] [Related]
51. Ethinylestradiol/cyproterone acetate in polycystic ovary syndrome: lipid and carbohydrate changes.
Villaseca P; Hormaza P; Cárdenas I; Oestreicher E; Arteaga E
Eur J Contracept Reprod Health Care; 2004 Sep; 9(3):155-65. PubMed ID: 15697105
[TBL] [Abstract][Full Text] [Related]
52. Oxidative stress in lung cancer patients is associated with altered serum markers of lipid metabolism.
Zabłocka-Słowińska K; Płaczkowska S; Skórska K; Prescha A; Pawełczyk K; Porębska I; Kosacka M; Grajeta H
PLoS One; 2019; 14(4):e0215246. PubMed ID: 30973911
[TBL] [Abstract][Full Text] [Related]
53. Plasma ghrelin concentrations in patients with polycystic ovary syndrome before and after 6months therapy: correlation with androgen levels.
Kos-Kudła B; Małecka-Mikosz O; Foltyn W; Ostrowska Z; Kudła M; Mazur B
Neuro Endocrinol Lett; 2006 Dec; 27(6):763-7. PubMed ID: 17187005
[TBL] [Abstract][Full Text] [Related]
54. Paraoxonase and arylesterase activity and total oxidative/anti-oxidative status in patients with chronic adenotonsillitis.
Koc S; Aksoy N; Bilinc H; Duygu F; Uysal IÖ; Ekinci A
Int J Pediatr Otorhinolaryngol; 2011 Nov; 75(11):1364-7. PubMed ID: 21893350
[TBL] [Abstract][Full Text] [Related]
55. Oxidative stress markers are not valuable markers in lean and early age of polycystic ovary syndrome patients.
Cakir E; Ozbek M; Ozkaya E; Colak N; Cakal E; Sayki M; Gungunes A; Aliyazicioglu Y; Mentese A; Delibasi T
J Endocrinol Invest; 2011; 34(7):e178-82. PubMed ID: 21088474
[TBL] [Abstract][Full Text] [Related]
56. Increased oxidative stress is associated with insulin resistance and infertility in polycystic ovary syndrome.
Özer A; Bakacak M; Kıran H; Ercan Ö; Köstü B; Kanat-Pektaş M; Kılınç M; Aslan F
Ginekol Pol; 2016; 87(11):733-738. PubMed ID: 27958630
[TBL] [Abstract][Full Text] [Related]
57. Comparison of two oral contraceptive forms containing cyproterone acetate and drospirenone in the treatment of patients with polycystic ovary syndrome: a randomized clinical trial.
Kahraman K; Sükür YE; Atabekoğlu CS; Ateş C; Taşkın S; Cetinkaya SE; Tolunay HE; Ozmen B; Sönmezer M; Berker B
Arch Gynecol Obstet; 2014 Aug; 290(2):321-8. PubMed ID: 24676694
[TBL] [Abstract][Full Text] [Related]
58. Are serum levels of ADAMTS5, TAS and TOS at 24-28 gestational weeks associated with adverse perinatal outcomes in gestational diabetic women?
Ozler S; Oztas E; Gumus Guler B; Erel O; Turhan Caglar A; Ergin M; Uygur D; Danisman N
J Obstet Gynaecol; 2020 Jul; 40(5):619-625. PubMed ID: 31526197
[TBL] [Abstract][Full Text] [Related]
59. The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia.
Panidis D; Georgopoulos NA; Piouka A; Katsikis I; Saltamavros AD; Decavalas G; Diamanti-Kandarakis E
Gynecol Endocrinol; 2011 Aug; 27(8):587-92. PubMed ID: 20836726
[TBL] [Abstract][Full Text] [Related]
60. Serum high-sensitivity C-reactive protein and homocysteine changes during hormonal therapy in women with polycystic ovary syndrome: a prospective, matched study.
Makedos A; Goulis DG; Papanikolaou A; Panidis D
Angiology; 2010 Aug; 61(6):595-601. PubMed ID: 20395229
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
